Sp499
HOW HAS FDA APPROVAL CHANGED THE LANDSCAPE OF MICROBIOME THERAPEUTICS
Date
May 19, 2024
Presenter
Brigham and Women's Hospital
Tracks
Related Products
SAFETY OUTCOMES AND CONCOMITANT MEDICATION CHANGES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEING TREATED WITH RBX2660 FOR RECURRENT <i>CLOSTRIDIOIDES DIFFICILE</i> INFECTION
BACKGROUND: Recurrent _Clostridioides difficile _infection (rCDI) is a debilitating disease associated with significant healthcare burden and low quality of life. The greatest risk factor for rCDI is a history of recurrence, although older age (≥65 years) and comorbidities also increase risk…
ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY
Background: We compared real-world outcomes of upadacitinib (upa) vs tofacitinib (tofa) for ulcerative colitis (UC) through 52 weeks…
Clostridioides Difficile Colitis: Pathogenesis, Diagnosis, Management and Therapy
This session will explore the role of the microbiome in the pathogenesis of Clostridioides difficile colitis, assess real-world data on novel microbiome therapeutics, and review innovative delivery modalities for these treatments…
